ETNB (89bio Inc) Net Profit

Official company branding of 89bio Inc (ETNB)

89bio, Inc. (ETNB) adheres to basic environmental standards, focusing on contractor safety. The development of targeted therapies for lipid disorders and liver pathologies reduces regulatory risks due to the variability of indications. The growth in business value is driven by the success of pegozafermin and the demand for MASH treatment. The organization's net income reflects fundamental value dynamics, while the -0.45 metric indicates the asset's status.

ETNB (89bio, Inc.) Company Net Income history from 07/04/2022 to 11/15/2025

Comprehensive metric breakdowns and analytics for 89bio (ETNB)

- price and consensus price forecast:
Stock Quotes 89bio Pharma|ETNB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization 89bio Pharma|ETNB - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share 89bio|ETNB - Company Book Value|Market Cap to Net Assets Ratio 89bio.com|ETNB - Company Total Assets
- debt and solvency information:
Debt to Capital 89bio, Inc.|ETNB - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio 89bio Inc|ETNB - Company Aggregate Debts|Debts to Book Capitalization 89bio Pharma|ETNB - Company Long-Term Debts|Company Short-Term Debt 89bio|Immediate Liquidity 89bio.com
- net income and valuation multiples indicators:
ETNB - Company Net Income
Fundamental valuation:89bio, Inc.
Signature product of 89bio.com

The profit of 89bio, Inc. reflects the final financial result after deducting all operating and non-operating expenses, serving as a key indicator of the business's ability to generate value. By analyzing the company's current profit, an investor can assess the financial stability of 89bio, Inc., which, given the clinical stages of development, depends critically on the efficiency of capital management and the success of drug trials for the FDA.

Direct competitors

Net Income Ascendis|MDGL (Madrigal Pharmaceuticals) - Net Profit|Net Profit corcept.com|Net Income RYTM (Rhythm Pharmaceuticals, Inc.)|AKRO (Akero Therapeutics, Inc.) - Final Profit|Company Net Income Metsera Corp MTSR|MLTX - Net Income|Crinetics Pharmaceuticals - Net Profit|Company Net Income newamsterdampharma.com|SLNO (Soleno Therapeutics, Inc.) - Net Income|FOLD: Profit After Payment of Taxes|AGIO (Agios Pharmaceuticals Inc) - Net Profit|Net Profit Structure Corp|Net Profit MDXG|Company Net Income RZLT (rezolutebio.com)|Company Net Income Lexicon Pharmaceuticals, Inc. LXRX|MBX Biosciences, Inc. (MBX) - Company Net Income|ALT - Company Net Income|AARD: Company Net Income|SGMT: Net Profit|BIOA - Net Financial Result|Company Net Income Biomea Fusion|Quince (QNCX) - Net Financial Result|Company Net Income Fractyl (GUTS)|Net Income vtvtherapeutics.com VTVT|Final Profit Agape ATP|Net Financial Result Pluristem Therapeutics (PLUR)|Synlogic Corp - Net Profit|LPCN: Company Net Income|MTNB: Net Profit|SPRB - Net Financial Result|Company Net Income Galecto, Inc.|Company Net Income carmellrx.com CTCX|Net Income LUMO (Lumos Pharma)|ONVO (Organovo Holdings) - Final Profit|Net Profit RDUS (Radius Health)